Form 4: Century Therapeutics CEO Sells Shares to Cover Tax Obligations Following RSU Vesting

Brent Pfeiffenberger, President and CEO of Century Therapeutics, Inc., sold 475 shares of common stock for tax withholding purposes related to restricted stock unit vesting.

Summary

• Brent Pfeiffenberger, President and CEO, and a Director of Century Therapeutics, Inc. (IPSC), reported a transaction on June 9, 2025.
• The transaction involved the disposition of 475 shares of Century Therapeutics common stock.
• The shares were sold at a price of $0.622 per share.
• Following this transaction, Mr. Pfeiffenberger directly beneficially owns 1,681,783 shares of common stock.
• The sale was non-discretionary and executed automatically to cover tax withholding obligations associated with the vesting of restricted stock units.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a mandatory, non-discretionary sale for tax purposes, not indicative of management's view on the company's future performance.

Positives

• The sale was non-discretionary and solely for tax withholding purposes, indicating it was not a voluntary divestment based on a negative outlook by the insider.

Negatives

• None directly from the transaction itself, as it was a mandatory tax-related sale.

Management Comments

• The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, common across all industries, including biotechnology. It does not provide specific insights into broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: Minimal direct impact as the sale was small (475 shares) and non-discretionary, not signaling a change in management's confidence.
• Employees: No direct impact indicated.

Key Dates

Keywords

Century Therapeutics, IPSC, Form 4, Insider Trading, Stock Sale, Restricted Stock Units, Tax Withholding, CEO, Director, Biotechnology, Pharmaceuticals